MD

In the past six months, Pediatrix Medical Group's stock saw a 56.58% increase over the past year, reaching $25.93 on September 18, 2026, from $16.56 on September 22, 2025. However, it decreased by 3.81% in the month leading up to October 6, 2026. On October 9, 2026, the stock price crossed above its 200-day moving average, reaching $26.35. The company exceeded Q1 2026 expectations with $0.63 adjusted EPS and $487.78 million in revenue, a 4.1% year-over-year increase. Analysts maintain a cautious 'Hold' rating with a consensus price target of $26.60, though some raised targets to $28 in July and August 2026. In July 2026, Pediatrix reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, confirming stable payor mix and no material changes in net revenue trends.